|
1
|
Zabrodskaya Y, Tsvetkov V, Shurygina AP, Vasyliev K, Shaldzhyan A, Gorshkov A, Kuklin A, Fedorova N, Egorov V. How the immune mousetrap works: Structural evidence for the immunomodulatory action of a peptide from influenza NS1 protein. Biophys Chem 2024; 307:107176. [PMID: 38219420 DOI: 10.1016/j.bpc.2024.107176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Accepted: 01/08/2024] [Indexed: 01/16/2024]
Abstract
One of the critical stages of the T-cell immune response is the dimerization of the intramembrane domains of T-cell receptors (TCR). Structural similarities between the immunosuppressive domains of viral proteins and the transmembrane domains of TCR have led several authors to hypothesize the mechanism of immune response suppression by highly pathogenic viruses: viral proteins embed themselves in the membrane and act on the intramembrane domain of the TCRalpha subunit, hindering its functional oligomerization. It has also been suggested that this mechanism is used by influenza A virus in NS1-mediated immunosuppression. We have shown that the peptide corresponding to the primary structure of the potential immunosuppressive domain of NS1 protein (G51) can reduce concanavalin A-induced proliferation of PBMC cells, as well as in vitro, G51 can affect the oligomerization of the core peptide corresponding to the intramembrane domain of TCR, using AFM and small-angle neutron scattering. The results obtained using in cellulo and in vitro model systems suggest the presence of functional interaction between the NS1 fragment and the intramembrane domain of the TCR alpha subunit. We have proposed a possible scheme for such interaction obtained by computer modeling. This suggests the existence of another NS1-mediated mechanism of immunosuppression in influenza.
Collapse
Affiliation(s)
- Yana Zabrodskaya
- Institute of Biomedical Systems and Biotechnology, Peter the Great Saint Petersburg Polytechnic University, 29 Ulitsa Polytechnicheskaya, St. Petersburg 194064, Russia; Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Ulitsa Prof. Popova, St. Petersburg 197376, Russia.
| | - Vladimir Tsvetkov
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Ulitsa Prof. Popova, St. Petersburg 197376, Russia; Federal Research and Clinical Center for Physical Chemical Medicine, 1a Ulitsa Malaya Pirogovskaya, Moscow 119435, Russia; Center for Mathematical Modeling in Drug Development, I.M. Sechenov First Moscow State Medical University, Moscow 119146, Russia
| | - Anna-Polina Shurygina
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Ulitsa Prof. Popova, St. Petersburg 197376, Russia
| | - Kirill Vasyliev
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Ulitsa Prof. Popova, St. Petersburg 197376, Russia
| | - Aram Shaldzhyan
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Ulitsa Prof. Popova, St. Petersburg 197376, Russia
| | - Andrey Gorshkov
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Ulitsa Prof. Popova, St. Petersburg 197376, Russia
| | - Alexander Kuklin
- International Intergovernmental Organization Joint Institute for Nuclear Research, 6 Ulitsa Joliot-Curie, Dubna 141980, Russia; Moscow Institute of Physics and Technology (State University), 9 Institutskiy pereulok, 141701 Dolgoprudny, Moscow Region, Russia
| | - Natalya Fedorova
- Petersburg Nuclear Physics Institute Named by B. P. Konstantinov of National Research Center, Kurchatov Institute, 1 mkr. Orlova Roshcha, Gatchina 188300, Russia
| | - Vladimir Egorov
- Institute of Experimental Medicine, 12 Ulitsa Akademika Pavlova, St. Petersburg 197376, Russia
| |
Collapse
|
|
2
|
Shaldzhyan A, Zabrodskaya Y, Yolshin N, Kudling T, Lozhkov A, Plotnikova M, Ramsay E, Taraskin A, Nekrasov P, Grudinin M, Vasin A. Clean and folded: Production of active, high quality recombinant human interferon-λ1. Process Biochem 2021; 111:32-39. [PMID: 34493923 PMCID: PMC8411590 DOI: 10.1016/j.procbio.2021.08.029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 08/30/2021] [Accepted: 08/31/2021] [Indexed: 12/09/2022]
Abstract
Type III interferons exhibit antiviral activity against influenza viruses, coronaviruses, rotaviruses, and others. In addition, this type of interferon theoretically has therapeutic advantages, in comparison with type I interferons, due to its ability to activate a narrower group of genes in a relatively small group of target cells. Hence, it can elicit more targeted antiviral or immunomodulatory responses. Obtaining biologically-active interferon lambda (hIFN-λ1) is fraught with difficulties at the stage of expression in soluble form or, in the case of expression in the form of inclusion bodies, at the stage of refolding. In this work, hIFN-λ1 was expressed in the form of inclusion bodies, and a simple, effective refolding method was developed. Efficient and scalable methods for chromatographic purification of recombinant hIFN-λ1 were also developed. High-yield, high-purity product was obtained through optimization of several processes including: recombinant protein expression; metal affinity chromatography; cation exchange chromatography; and an intermediate protein refolding stage. The obtained protein was shown to feature expected specific biological activity in line with published effects: induction of MxA gene expression in A549 cells and antiviral activity against influenza A virus.
Collapse
Affiliation(s)
- Aram Shaldzhyan
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Yana Zabrodskaya
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.,Peter the Great Saint Petersburg Polytechnic University, 29 Polytechnicheskaya, St. Petersburg, 194064, Russia.,Petersburg Nuclear Physics Institute named by B. P. Konstantinov of National Research Center "Kurchatov Institute", mkr. Orlova roshcha 1, Gatchina, 188300, Russia
| | - Nikita Yolshin
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Tatiana Kudling
- Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
| | - Alexey Lozhkov
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.,Peter the Great Saint Petersburg Polytechnic University, 29 Polytechnicheskaya, St. Petersburg, 194064, Russia
| | - Marina Plotnikova
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Edward Ramsay
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Aleksandr Taraskin
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.,Peter the Great Saint Petersburg Polytechnic University, 29 Polytechnicheskaya, St. Petersburg, 194064, Russia
| | - Peter Nekrasov
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Mikhail Grudinin
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia
| | - Andrey Vasin
- Smorodintsev Research Institute of Influenza, Russian Ministry of Health, 15/17 Prof. Popov St., St. Petersburg, 197376, Russia.,Peter the Great Saint Petersburg Polytechnic University, 29 Polytechnicheskaya, St. Petersburg, 194064, Russia
| |
Collapse
|
|
3
|
Shanko A, Shuklina M, Kovaleva A, Zabrodskaya Y, Vidyaeva I, Shaldzhyan A, Fadeev A, Korotkov A, Zaitceva M, Stepanova L, Tsybalova L, Kordyukova L, Katlinski A. Comparative Immunological Study in Mice of Inactivated Influenza Vaccines Used in the Russian Immunization Program. Vaccines (Basel) 2020; 8:vaccines8040756. [PMID: 33322762 PMCID: PMC7768547 DOI: 10.3390/vaccines8040756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 11/26/2020] [Accepted: 12/09/2020] [Indexed: 11/16/2022] Open
Abstract
A series of commercial inactivated influenza vaccines (IIVs) used in the Russian National Immunization Program were characterized to evaluate their protective properties on an animal model. Standard methods for quantifying immune response, such as hemagglutination inhibition (HAI) assay and virus neutralization (VN) assay, allowed us to distinguish the immunogenic effect of various IIVs from that of placebo. However, these standard approaches are not suitable to determine the role of various vaccine components in immune response maturation. The expanded methodological base including an enzyme-linked immunosorbent assay (ELISA) and a neuraminidase ELISA (NA-ELISA) helped us to get wider characteristics and identify the effectiveness of various commercial vaccines depending on the antigen content. Investigations conducted showed that among the IIVs tested, Ultrix®, Ultrix® Quadri and VAXIGRIP® elicit the most balanced immune response, including a good NA response. For Ultrix®, Ultrix® Quadri, and SOVIGRIPP® (FORT LLC), the whole-virus specific antibody subclass IgG1, measured in ELISA, seriously prevailed over IgG2a, while, for VAXIGRIP® and SOVIGRIPP® (NPO Microgen JSC) preparations, the calculated IgG1/IgG2a ratio was close to 1. So, the immune response varied drastically across different commercial IIVs injected in mice.
Collapse
Affiliation(s)
- Andrei Shanko
- Research and Development Department, FORT LLC, 119435 Moscow, Russia
- N. F. Gamaleya Federal Research Center for Epidemiology and Microbiology, Ivanovsky Institute of Virology, 123098 Moscow, Russia
- Correspondence: ; Tel.: +7-916-196-24-21
| | - Marina Shuklina
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Anna Kovaleva
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Yana Zabrodskaya
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
- Peter the Great Saint-Petersburg Polytechnical University, 194064 Saint-Petersburg, Russia
- Petersburg Nuclear Physics Institute named by B. P. Konstantinov of National Research Center “Kurchatov Institute”, 188300 Gatchina, Russia
| | - Inna Vidyaeva
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Aram Shaldzhyan
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Artem Fadeev
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Alexander Korotkov
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Marina Zaitceva
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Liudmila Stepanova
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Liudmila Tsybalova
- WHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia; (M.S.); (A.K.); (Y.Z.); (I.V.); (A.S.); (A.F.); (A.K.); (M.Z.); (L.S.); (L.T.)
| | - Larisa Kordyukova
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow, Russia;
| | | |
Collapse
|